The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Scott Henry - Alliance Global Partners - Analyst
: Thank you and good afternoon. I guess for starters now that we're into 2024. Do you have any guidance for the year or how we should think about
revenues? And within that, obviously, first quarter is just a couple of days from being complete, maybe how we should think about first quarter
relative to that just completed fourth quarter?
Question: Scott Henry - Alliance Global Partners - Analyst
: Kate Spargo again, I appreciate the color you perhaps just asking it a little different with little just different spin on it first quarter, because a lot of
these initiatives are going to take time. Should we expect first quarter 24 to look similar to fourth quarter 23. And also, as you mentioned, the goal
of profitability, I guess in Q4, what sort of quarterly revenue number do you need to get to profitability.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 28, 2024 / 9:00PM, VVOS.OQ - Q4 2023 Vivos Therapeutics Inc Earnings Call
Question: Scott Henry - Alliance Global Partners - Analyst
: And as far as what was the last part of your question, I don't recall what quarterly revenue number would would you need to reach a cash flow
breakeven from operations?
Question: Scott Henry - Alliance Global Partners - Analyst
: So.
Okay, great. And then the fourth quarter is always the hardest to figure out because you got to kind of back it out of the other three quarters, but
it looks like the suite testing services ticked up in a material way in Q4. Am I interpreting that correct?
It would you expect it to continue at these higher levels? Or was that a kind of a onetime?
Okay.
Question: Scott Henry - Alliance Global Partners - Analyst
: Okay. Great. Thank you for taking the questions.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 28, 2024 / 9:00PM, VVOS.OQ - Q4 2023 Vivos Therapeutics Inc Earnings Call
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Thank you.
Good afternoon, gentlemen, and congratulations on the tremendous progress that you're making in the business.
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: And I am You're welcome to I mean, it's just an amazing situation with the Philips recall and you know, at the same time you get this five 10 K
clearance for the oral appliances for severe sleep apnea. It just so in theory, there's millions of people that would be looking for an alternative, but
we don't really see any sign of it yet in the financials, and I'm sure it's frustrating to you as well. I guess as an analyst, I'm just trying to understand
like, you know, what is the scale of the opportunity? And what is the timing in terms of seeing the the wave of people coming over, let's say, from
from CPAP. to Vivo's?
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Yes.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 28, 2024 / 9:00PM, VVOS.OQ - Q4 2023 Vivos Therapeutics Inc Earnings Call
Okay.
I guess related to that than some of the specific initiatives unit announced the partnerships, you've got Orco new LYNN care, Deca. Could you give
us an update on some of those external partnerships and what you see happening in 2024?
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Wonderful, if I may, I was wondering about the AFD. acquisition sort of nine months on whatever it is, you know, I guess maybe it's almost a year.
How's that going from a revenue standpoint? Obviously you don't break it out, but are you is it the is are you as pleased with it now as you were
at the beginning?
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Sure.
Okay.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 28, 2024 / 9:00PM, VVOS.OQ - Q4 2023 Vivos Therapeutics Inc Earnings Call
One more question on the expense side. It looks like we're it was about $6.1 million in operating expenses for Q4. I'm just wondering where you
see that bottoming out. Can that continue to go down? And are we are we kind of at bottom already with them total operating expenses on a
quarterly basis.
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay, KIRK.
Thanks.
Thank you, Brad.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 28, 2024 / 9:00PM, VVOS.OQ - Q4 2023 Vivos Therapeutics Inc Earnings Call
| 
